The PrePsia test measures biomarkers which allow it to identify preeclampsia risk in the sub population of obese women. The discovery of these markers supports the insight that preeclampsia is most likely syndromic in nature, having multiple different origins (e.g. obesity, placental insufficiency, maternal health) and manifesting in different ways (e.g. preterm, term, post-partum).
Metabolomic Diagnostics recognises that different biomarkers may be sensitive to different combinations of these characteristics and therefore continues to research algorithms which will allow us to detect them.
Through this work we hope to release future versions of PrePsia which will extend the utility of PrePsia beyond the obese population and to provide even more targeted information.